Patents Assigned to The University of Liverpool
-
Patent number: 10449198Abstract: The present invention relates to a method of treating pain in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate: wherein Q is as defined herein.Type: GrantFiled: July 5, 2017Date of Patent: October 22, 2019Assignee: The University of LiverpoolInventors: Martin Leuwer, Paul O'Neill, Neil Berry, Chandrakala Pidathala
-
Patent number: 10442814Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.Type: GrantFiled: April 13, 2018Date of Patent: October 15, 2019Assignee: University of LiverpoolInventors: Martin Leuwer, Paul M. O'Neill, Neil Berry, Chandrakala Pidathala
-
Patent number: 10398559Abstract: A method of forming an implant having a porous tissue ingrowth structure and a bearing support structure. The method includes depositing a first layer of a metal powder onto a substrate, scanning a laser beam over the powder so as to sinter the metal powder at predetermined locations, depositing at least one layer of the metal powder onto the first layer and repeating the scanning of the laser beam.Type: GrantFiled: May 13, 2014Date of Patent: September 3, 2019Assignees: Howmedica Osteonics Corp., The University Of LiverpoolInventors: Eric Jones, Christopher J. Sutcliffe, Robin Stamp
-
Patent number: 10370422Abstract: Provided are compositions comprising fusion proteins, polynucleotides and/or expression vectors with therapeutic utility for suppressing and/or treating cancer, as well as medical uses of these agents, and methods of treatment in which they are used. A fusion protein of the invention comprises an amino acid sequence that provides the apoptosis-inducing activity of TRAIL, and a membrane-anchoring amino acid sequence. The amino acid sequence that provides the apoptosis-inducing activity of TRAIL comprises the extracellular domain of TRAIL, or a fragment or variant thereof. A fusion protein comprising an amino acid sequence from TRAIL that is able to induce apoptosis, and a second sequence that anchors the first sequence to the cell membrane, is markedly more effective at reducing viability of TRAIL receptor positive cells than the naturally occurring (“wild type”) TRAIL protein itself.Type: GrantFiled: April 15, 2015Date of Patent: August 6, 2019Assignee: The University of LiverpoolInventors: Daniel Palmer, Taha Elmitwalli
-
Patent number: 10363315Abstract: The present invention relates to a composition for use in the treatment of a detached retina, comprising an oil and an additive capable of increasing the extensional viscosity of the oil. The present invention also relates to a method and kit of parts for producing the composition.Type: GrantFiled: May 18, 2006Date of Patent: July 30, 2019Assignee: University of LiverpoolInventors: Michael Joseph Garvey, Rachel Lucinda Williams, Michael Day
-
Publication number: 20190218323Abstract: The present invention relates to a branched amphiphilic polymer, suitable for stabilizing an emulsion, comprising a plurality of polymer chains comprising hydrophobic chain ends; a plurality of polymer chains comprising functional chain ends capable of associating to a biological substrate; and a plurality of branching units. The present invention also relates to pharmaceutical compositions containing said branched amphiphilic polymers, their methods of use, and methods for their preparation.Type: ApplicationFiled: August 8, 2017Publication date: July 18, 2019Applicant: The University of LiverpoolInventors: Stephanie Edwards, Steve Rannard, Andrew Owen
-
Publication number: 20190175497Abstract: A composition comprises: a base oil; an additive comprising a copolymer comprising hydrophobic and hydrophilic units; and a drug. The copolymer may for example have a comb structure in which the hydrophobic units and hydrophilic units are pendant chains on a backbone of the copolymer. The hydrophobic units and hydrophilic units may for example comprise polydimethylsiloxane moieties and ethylene glycol residues respectively. The composition may for example be used as a tamponade or as a component for a tamponade administered to the eye. The invention is useful for solubilising and/or releasing drugs.Type: ApplicationFiled: August 9, 2017Publication date: June 13, 2019Applicant: The University of LiverpoolInventors: Victoria Kearns, Helen Cauldbeck, Steve Rannard, Rachel Williams, Maude Le Hellaye
-
Publication number: 20190175742Abstract: A composition comprises: a base oil; an additive; and a drug. The additive has segments which are conjugated, e.g. covalently linked, together. A first segment facilitates solubility in the base oil, whereas a second segment facilitates drug solubility and/or modifies drug release or other behaviour. The first segment may for example comprise a poly(dimethylsiloxane)-containing moiety. The second segment may for example resemble a drug molecule. The composition may for example be used as a tamponade or as a component for a tamponade administered to the eye.Type: ApplicationFiled: August 9, 2017Publication date: June 13, 2019Applicant: The University of LiverpoolInventors: Victoria Kearns, Helen Cauldbeck, Steve Rannard, Rachel Williams, Maude Le Hellaye
-
Publication number: 20190134014Abstract: The invention provides anelastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy, as well as a method for promoting muscle regeneration in a subject with a myopathy, the method comprising providing the subject with a therapeutically effective amount of an elastase inhibitor. Further provided is a pharmaceutical composition comprising anelastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy. Elastase inhibitors may have a protective effect on muscle progenitor cells and their regenerative potential, which aids muscle cell regeneration. By protecting regenerative potential of muscle progenitor cells, elastase inhibitors enable or enhance the grown of new or existing muscle fibres.Type: ApplicationFiled: May 15, 2017Publication date: May 9, 2019Applicant: THE UNIVERSITY OF LIVERPOOLInventor: Addolorata PISCONTI
-
Publication number: 20190084993Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.Type: ApplicationFiled: April 13, 2018Publication date: March 21, 2019Applicant: The University of LiverpoolInventors: Martin Leuwer, Paul M. O'Neill, Neil Berry, Chandrakala Pidathala
-
Patent number: 10181618Abstract: A method of preparing a porous carbon material is provided. The method comprises a) freezing a liquid mixture comprising a polymer suspended or dissolved in a solvent to form a frozen mixture; b) removing the solvent from the frozen mixture to form a porous frozen mixture; and c) pyrolyzing the porous frozen mixture to obtain the porous carbon material. A porous carbon material prepared using the method, and uses of the porous carbon material are also provided.Type: GrantFiled: July 29, 2015Date of Patent: January 15, 2019Assignees: Agency for Science, Technology and Research, The University of LiverpoolInventors: Aled Deakin Roberts, Suxi Wang, Haifei Zhang, Xu Li
-
Patent number: 9994624Abstract: The present invention relates to vaccines comprising a ShK domain of a filarial nematode protein. These vaccines may be used for the prevention and/or treatment of filarial nematode infections. The invention also relates to novel proteins comprising a ShK domain of a filarial nematode protein and pharmaceutical compositions. The invention may be used for the prevention and/or treatment of filarial nematode infections in canine subjects, and also in human subjects.Type: GrantFiled: February 11, 2015Date of Patent: June 12, 2018Assignees: THE UNIVERSITY OF LIVERPOOL, EDINBURGH UNIVERSITYInventors: Ben Makepeace, David Taylor, Simon Babayon, Stuart Armstrong, Mark Blaxter
-
Patent number: 9981243Abstract: The present invention relates to compounds capable of forming metal-organic frameworks (MOFs), particularly f-block metal MOFs which selectively sorb one component (e.g. para-xylene) from a mixture of components (e.g. m-/p-xylene mixture). The invention also relates to methods of producing and using said compounds.Type: GrantFiled: August 2, 2017Date of Patent: May 29, 2018Assignee: The University of LiverpoolInventors: Matthew J. Rosseinsky, Catherine G. Perkins, John Edward Warren, Kim Elizabeth Jelfs, Paul Boldrin
-
Patent number: 9981957Abstract: The present invention relates to a process for preparing substituted piperidine compounds and especially chiral substituted piperidine compounds. The process involves reacting a substituted pyridinium ion with an amine as defined herein, in the presence of a hydrogen donor, a catalysts and a suitable solvent.Type: GrantFiled: March 24, 2015Date of Patent: May 29, 2018Assignee: THE UNIVERSITY OF LIVERPOOLInventors: Jianliang Xiao, Jianjun Wu
-
Patent number: 9944653Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.Type: GrantFiled: May 4, 2017Date of Patent: April 17, 2018Assignee: THE UNIVERSITY OF LIVERPOOLInventors: Martin Leuwer, Paul O'Neill, Neil Berry, Chandrakala Pidathala
-
Patent number: 9889150Abstract: The present invention relates to the use of agents (including heparin derivatives) for the prevention and/or treatment of CNS damage.Type: GrantFiled: November 1, 2013Date of Patent: February 13, 2018Assignees: The University Of Liverpool, The University Court of the University of GlasgowInventors: Jeremy Ewan Turnbull, Scott Ernest Guimond, Sophie Marie Thompson, Susan Carol Barnett, Jennifer Rosemary Higginson
-
Publication number: 20180038839Abstract: An embodiment of the present invention provides a method of creating a classifier indicative of a presence of a medical condition in a subject, comprising receiving chromatogram data indicative of a profile of volatile organic compounds in a sample from each of a first plurality of subjects having the medical condition and a second plurality of subjects without the medical condition, selecting one of the chromatogram data as reference chromatogram data, aligning the remaining chromatogram data in relation to the reference chromatogram data, extracting one or more features from the chromatogram data using a Mexican hat wavelet transform of one or more scales, selecting one or more features of the chromatogram data indicative of the medical condition, and constructing a classifier for determining a boundary between chromatogram data indicative of the medical condition and chromatogram data indicative of an absence of the medical condition.Type: ApplicationFiled: February 12, 2016Publication date: February 8, 2018Applicant: University of Liverpool, Inst. Translation MedicInventors: Christopher Simon John Probert, Raphael Bastos Mareschi Aggio
-
Patent number: 9879041Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit ?-secretase.Type: GrantFiled: November 28, 2013Date of Patent: January 30, 2018Assignees: Victoria Link Limited, University of LiverpoolInventors: Peter Charles Tyler, Olga Vladimirovna Zubkova, Jeremy E. Turnbull
-
Publication number: 20180021261Abstract: An oil-in-water emulsion comprises an emulsifier which is a non-gelled branched polymer (e.g. a branched vinyl polymer), wherein the ends of at least some of the chains of said polymer terminate in an alkyl chain of 5 carbon atoms or more, and wherein the oil-in-water emulsion takes the form of particles having a z-average diameter of no greater than about 1000 nm. This is useful in, for example, facilitating the carrying of hydrophobic materials within aqueous systems, to enhance oral drug delivery. The oil-in-water emulsion may be prepared by mixing an oil phase with an aqueous phase in the presence of an emulsifier, wherein said emulsifier is a non-gelled branched polymer, wherein the ends of at least some of the chains of said polymer terminate in an alkyl chain of 5 carbon atoms or more, and wherein the oil-in-water emulsion takes the form of particles having a z-average diameter of no greater than about 1000 nm.Type: ApplicationFiled: February 3, 2016Publication date: January 25, 2018Applicant: The University of LiverpoolInventors: Steve Rannard, Andrew Owen, James Hobson, Neill Liptrott, Pierre Chambon
-
Patent number: 9820939Abstract: The present invention provides a composition and an antiviral drug preparation, each comprising at least one water-insoluble antiviral drug and at least one water-soluble carrier material, wherein the water-insoluble antiviral drug is dispersed through the water-soluble carrier material in nano-disperse form. The present invention further provides processes for preparing the compositions and drug preparations, and also aqueous nano-dispersions obtained by combining water and the compositions.Type: GrantFiled: September 23, 2015Date of Patent: November 21, 2017Assignee: The University of LiverpoolInventors: Alison J. Foster, James Long, Steven P. Rannard, Dong Wang, David J. Duncalf, Andrew Owen